文献速递药疹与重症皮肤不良反应

基于SCORTEN的SJS/TEN系统治疗系统综述与荟萃分析

Systemic therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN-based systematic review and meta-analysis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-07-23

该研究通过SCORTEN评分系统评估SJS/TEN多种免疫调节疗法的有效性,纳入38项研究共1827例患者。荟萃分析显示环孢素、依那西普及免疫球蛋白联合糖皮质激素的log(SMR)值较低,但网络荟萃分析中无治疗显著降低SMR。证据尚不足以推荐广泛使用。

要点

  • 环孢素和免疫球蛋白联合糖皮质激素与SCORTEN预测死亡相比死亡更少。
  • 网络荟萃分析中无任何治疗达到显著降低SMR。
  • 证据不足以推荐所有患者广泛使用这些疗法。

核心结论

  • 部分SJS/TEN治疗表现较好,但证据不足以推荐广泛使用于所有患者。

研究设计与样本

  • 系统综述与荟萃分析,检索原始研究,最终合并38项研究共1827例SJS/TEN患者。

主要发现

  • 荟萃分析log(SMR)值:糖皮质激素-0.13(95%CI -0.42,0.16),免疫球蛋白-0.39(95%CI -0.87,0.09),支持治疗0.13(95%CI -0.15,0.40)。
  • 环孢素log(SMR)为-0.88(95%CI -1.47,-0.29),依那西普为-0.95(95%CI -1.82,-0.07),免疫球蛋白联合糖皮质激素为-0.56(95%CI -0.94,-0.19)。
  • Meta回归分析证实环孢素和免疫球蛋白联合糖皮质激素与SCORTEN预测死亡相比死亡更少。
  • 网络荟萃分析中无治疗达到显著降低SMR。

临床怎么用

  • 临床决策时可参考SCORTEN评分及本荟萃分析结果,但需注意证据局限性。

局限性

  • 纳入研究存在异质性和质量差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The SCORTEN score is a specific predictor of mortality for patients with Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). There is little evidence in support of the common immunomodulating therapies for SJS/TEN. OBJECTIVES: To systematically assess the effectiveness of several therapies for SJS/TEN through the SCORTEN score. METHODS: Databases were searched for original studies on the use of SCORTEN. Six meta-analyses were carried out on patients with SJS/TEN who received supportive care only or in combination with immunomodulating drugs: corticosteroids, cyclosporine, etanercept, immunoglobulins or a combination of corticosteroids with immunoglobulins. A multivariate meta-regression and a network meta-analysis were also performed. RESULTS: Of 3893 studies identified, fifty-two involving 2466 patients with SJS/TEN were preselected. Data from thirty-eight of these studies (1827 patients) were finally pooled, and results [log(SMR)] from meta-analyses were as follows: -0.13 (95% CI, -0.42,0.16) for corticosteroids, -0.39 (95% CI, -0.87,0.09) for immunoglobulins, 0.13 (95% CI, -0.15,0.40) for supportive treatment, -0.88 (95% CI, -1.47, -0.29) for cyclosporine, -0.95 (95% CI, -1.82, -0.07) for etanercept and - 0.56 (95% CI, -0.94, -0.19) for immunoglobulins plus corticosteroids. The meta-regression analysis confirmed that cyclosporine and immunoglobulins plus corticosteroids were associated with less deaths than predicted by SCORTEN. In the network meta-analysis, no treatment achieved a significant reduction in the SMR. LIMITATIONS: Heterogeneity and quality of the included studies. CONCLUSIONS: Some treatments for SJS/TEN show a better performance, but there is not sufficient evidence to recommend its widespread use in all patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Torres-Navarro I, Briz-Redón Á, Botella-Estrada R, et al. Systemic therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN-based systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020. PMID: 32946187. doi:10.1111/jdv.16685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。